T
Toripalimab
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Availability of ACE Drug Guidance
Yes
Post-marketing information
Patient Medication Guide
Biologics Drug Information Overview
Yes
Active ingredient: Toripalimab
General information
Subsidy Information and Financing Scheme
[MSHL] Toripalimab Concentrate For Solution For Infusion 240 mg/6 mL
Toripalimab in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Maximum treatment duration with toripalimab is 24 months.
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended toripalimab in combination with chemotherapy for inclusion on the MOH List of Subsidised Drugs for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma. The decision was based on the unfavourable cost effectiveness of toripalimab plus chemotherapy compared with chemotherapy alone, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for toripalimab plus chemotherapy are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Loqtorzi Concentrate For Solution For Infusion 240 mg/6 mL |
|